New clotting factor aims to cut bleeding episodes in severe hemophilia a
NCT ID NCT07684898
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This phase 3 trial tests a new drug called FRSW107, a long-lasting version of clotting factor VIII, in people with severe hemophilia A. The study enrolls males aged 12 to 65 who have had at least 150 prior exposure days to factor VIII products. Participants receive regular injections of FRSW107 every three days to prevent bleeding episodes, and researchers track how well it works, its safety, and its impact on quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recombinant human coagulation factor VIII-Fc fusion protein (FRSW107)
- What this could lead to
- If successful, this could provide a more effective and convenient preventive treatment to reduce bleeding episodes in people with severe hemophilia A.
- What could go wrong
- This is a single-arm, open-label trial with no placebo comparison, so results may be less definitive. The treatment requires regular injections every three days, and there is a risk of developing inhibitors that reduce effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Affiliated Hospital of Jiangnan University
NOT_YET_RECRUITINGWuxi, China
Contact
-
Affiliated Hospital of Nantong University
NOT_YET_RECRUITINGNantong, China
Contact
-
Anhui Provincial Hospital
NOT_YET_RECRUITINGHefei, China
Contact
-
Fujian Medical University Union Hospital
NOT_YET_RECRUITINGFuzhou, China
Contact
-
Fuyang Hospital, Affiliated to Anhui Medical University
NOT_YET_RECRUITINGFuyang, China
Contact
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, China
Contact
-
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGTianjin, Tianjin Municipality, China
Contact
-
Jinan central hospital
NOT_YET_RECRUITINGJinan, China
Contact
-
Nanfang Hospital of Southern Medical University
NOT_YET_RECRUITINGGuangzhou, China
Contact
-
North China University of Science and Technology Affiliated Hospital
NOT_YET_RECRUITINGTangshan, China
Contact
-
Qinghai Provincial People's Hospital
NOT_YET_RECRUITINGQinghai, China
Contact
-
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITINGNanning, China
Contact
-
The First Affiliated Hospital of Nanyang Medical College
NOT_YET_RECRUITINGNanyang, China
Contact
-
The Second Affiliated Hospital of Kunming Medical University
NOT_YET_RECRUITINGKunming, China
Contact
-
The Second Hospital of Shanxi Medical University
NOT_YET_RECRUITINGTaiyuan, China
Contact
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology.
NOT_YET_RECRUITINGWuhan, China
Contact
-
Wenzhou People's Hospital
NOT_YET_RECRUITINGWenzhou, China
Contact
-
Xi'an Central Hospital
NOT_YET_RECRUITINGXi'an, China
Contact
-
Zhengzhou People's Hospital
NOT_YET_RECRUITINGZhengzhou, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New clotting factor aims to stop bleeding in severe hemophilia a
- New clotting factor shows promise for hemophilia a bleeds
- Blood test may predict bleeding risk in hemophilia a patients on emicizumab
- Hemophilia a bone health under the microscope: which treatment wins?
- One-Shot gene therapy aims to fix bleeding disorder
- Weekly shot could transform bleeding prevention for kids with hemophilia